Erasure, establishment and maintenance of genetic imprinting are indispensable for normal embryonic development. All these processes depend on accurate expression and intimate cooperation of kinds of DNA methyltransferases. Many genetic syndromes and embryo developmental anomalies are caused by abnormality of genetic imprinting. Genetic imprinting is important for the nucleus totipotential of primordial germ cell, maturation of gamete,growth and development of embryo, structure and function of placenta as well as postnatal growth and development of individuals.
Animals ; DNA Methylation ; DNA Modification Methylases ; genetics ; metabolism ; Embryonic Development ; genetics ; Genomic Imprinting ; genetics ; Humans ; Mutation

OBJECTIVE: To analyze the effect of DNA hypermethylation on NOR1 promoter activity and expression. METHODS: NOR1 promoter plasmids were treated with SssI methyltransferase. The plasmids were modified by sodium bisulfite and purified. Sodium bisulfite-modified plasmids were subjected to PCR with primers designed to analyze the methylation status of 26 CpG sites in a 311-bp region of the NOR1 promoter. Cells were transfected by methylated or mock-methylated promoter plasmids. The promoter activities were assessed by the luciferase levels of cell lysates or by directly observing GFP expression under fluorescence microscope. HL60 cells were treated with different concentrations of 5-aza-dC. Total RNA was isolated from harvested cells. Real-time RT-PCR was used to measure the expression level of NOR1 mRNA. RESULTS: Bisulfite sequencing confirmed that SssI methyltransferase treatment successfully resulted in intensive hypermethylation of the NOR1 promoter plasmids. The promoter activity of NOR1 promoter plasmids was totally blocked by SssI methyltransferase treatment. NOR1 expression levels in HL60 cells were restored by 5-aza-dC treatment. CONCLUSION NOR1 promoter plasmids are intensively hypermethylated by SssI methyltransferase treatment. The promoter activity of NOR1 promoter plasmids are totally blocked by SssI methyltransferase treatment. The 5-aza-dC treatment may restore the endogenous NOR1 mRNA level in HL60 cells.
Azacitidine ; analogs & derivatives ; pharmacology ; Base Sequence ; Cell Line, Tumor ; CpG Islands ; DNA Methylation ; DNA Modification Methylases ; antagonists & inhibitors ; DNA-Cytosine Methylases ; pharmacology ; Decitabine ; Epigenesis, Genetic ; Gene Silencing ; HL-60 Cells ; Humans ; Membrane Transport Proteins ; genetics ; metabolism ; Molecular Sequence Data ; Nasopharyngeal Neoplasms ; pathology ; Promoter Regions, Genetic ; genetics ; RNA, Messenger ; genetics ; metabolism

The RNA-directed DNA Methylation (RdDM) is one type of epigenetic modification which was firstly discovered in plant. RdDM can directly cause DNA modifications of the genome through RNA-DNA interactions. In plant, both of RdDM and mRNA degradation induced by siRNA can silence sequence specific genes through RNA. They play very significant roles in chromosome rearrangement, defence of virus invasion, regulation of gene expression and many processes of plant development. However, the mechanisms of RdDM are still unclear. In this paper the basic characteristics of RdDM were briefly summarized and advances in studies on mechanisms of RdDM were reviewed. These include the kinds of DNA methyltransferases and their functional mechanisms in RdDM, the relationships between DNA methylation and chromatin modification, and important proteins involved in the RdDM process. In plants, RdDM may occur at both the transcriptional and post-transcriptionnal levels, both of which induce gene silencing. Methylation of the target gene promoter correlates with transcriptional gene silencing (TGS) whereas methylation of the coding sequence is associated with post-transcriptional gene silencing (PTGS). RdDM and RNAi all depend on the similar siRNA and enzymes, such as DCL3, RdR2, SDE4 and AGO4. There are at least three kinds of DNA methyltransferases, DRM1/2, MET1 and CMT3, in pants. They can interact with and modifies all cytidines within the DNA regions homologous to RNA sequence. Furthermore, methylation of lysine 9 in Histone H3 can affect the methylation of cytidines.
DNA Methylation ; DNA Modification Methylases ; metabolism ; Gene Silencing ; Plants ; genetics ; metabolism ; Protein Processing, Post-Translational ; RNA ; metabolism

Findings in epigenetic changes in meylodysplastic syndromes (MDS) and the development of demethylating drugs provide a new approach to the treatment of MDS. We used standard-dose decitabine for treatment of MDS in an elderly patient with an International Prostate Symptom Score (IPSS) of moderate risk group 2, and achieved a complete response in the first course. We report our experience with this case and review the relevant literatures.
Azacitidine ; analogs & derivatives ; therapeutic use ; DNA Modification Methylases ; antagonists & inhibitors ; Female ; Humans ; Middle Aged ; Myelodysplastic Syndromes ; drug therapy

DNA Methylation ; DNA Modification Methylases ; genetics ; DNA Repair Enzymes ; genetics ; Humans ; Neoplasms ; genetics ; Prognosis ; Promoter Regions, Genetic ; Tumor Suppressor Proteins ; genetics

OBJECTIVETo compare the sensitivity of different hepatocellular carcinoma (HCC) cell lines (HepG2, QGY7701, HepG2.2.15) and the normal liver cell line L02 to 5-aza-dC, an DNA methyltransferase inhibitor, and to explore the relationship between global DNA methylation level and the sensitivity to 5-aza-dC.

METHODSHepG2, QGY7701, HepG2.2.15 and L02 cells were treated with 5-aza-dC at different concentration, cell proliferation was measured by MTT method, cell apoptosis was detected by measuring caspase 3 activity and cellular DNA fragmentation ELISA.

RESULTSCompared to HepG2 and QGY7701 cells, HepG2.2.15 were less sensitive to the treatment of 5-aza-dC; the normal liver cell line L02 was less sensitive to 5-aza-dC than the HCC cell lines.

CONCLUSIONSThe sensitivity to 5-aza-dC of HCC cell lines and normal liver cells is not correlated with the global DNA methylation level.

Azacitidine ; analogs & derivatives ; pharmacology ; Carcinoma, Hepatocellular ; metabolism ; Caspase 3 ; metabolism ; DNA Methylation ; drug effects ; DNA Modification Methylases ; antagonists & inhibitors ; Hep G2 Cells ; Humans

BACKGROUND: O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation is currently the most promising predictive marker for the outcome and benefit from temozolomide treatment in patients with glioblastoma, but there is no consensus on the analysis method for assessing the methylation status in the molecular diagnostic field. The objective of this study was to evaluate methylation-specific polymerase chain reaction (MSP) and pyrosequencing methods for assessing MGMT gene promotor methylation of glioblastoma as well as assessing the MGMT protein expression by immunohistochemistry. METHODS: Twenty-seven cases of glioblastoma from the archives at the Department of Pathology Konkuk University Hospital were selected. MGMT promoter methylation was evaluated by MSP and the pyrosequencing methods. The MGMT expression was also measured at the protein level by immunohistochemistry. RESULTS: Overall, MGMT hypermethylation was observed in 44.4% (12/27 cases) of the case of glioblastoma using either MSP or pyrosequencing. The concordant rate was 70.3% (19/27 cases) between MSP and pyrosequencing for MGMT methylation. There was no correlation between MGMT methylation and the protein expression. No significant differences in progression free survival and overall survival were seen between the methylated group and the unmethylated group by using either MSP or pyrosequencing. The status of the MGMT protein expression was correlated with progression free survival (p=0.026). CONCLUSIONS: In this study the concordance rate between MSP and the pyrosequencing methods for assessing MGMT gene promotor methylation was relatively low for the cases of glioblastoma. This suggests that more reliable techniques for routine MGMT methylation study of glioblastoma remain to be developed because of quality control and assurance issues.
Consensus ; Dacarbazine ; Disease-Free Survival ; DNA Modification Methylases ; DNA Repair Enzymes ; Glioblastoma ; Humans ; Methylation ; Pathology, Molecular ; Polymerase Chain Reaction ; Quality Control ; Tumor Suppressor Proteins

The occurrence and development of acute myeloid leukemia (AML) is not only related to gene mutations, but also influenced by abnormal epigenetic regulation, in which DNA methylation is one of the most important mechanisms. Abnormal DNA methylation may lead to the activation of oncogene and the inactivation of tumor suppressor gene, resulting in the occurrence of leukemia. The mutations of DNA methylation enzymes associated with AML may have certain characteristics. The AML with recurrent cytogenetic abnormalities is also related to abnormal methylation. Some fusion genes can alter DNA methylation status to participate in the pathogenesis of leukemia. In addition, chemotherapy drug resistance in patients with AML is associated with the change of gene methylation status. Considering the reversibility of the epigenetic modification, targeted methylation therapy has become a hotspot of AML research.
DNA Methylation ; drug effects ; genetics ; physiology ; DNA Modification Methylases ; genetics ; physiology ; Drug Resistance, Neoplasm ; genetics ; Epigenesis, Genetic ; genetics ; physiology ; Humans ; Leukemia, Myeloid, Acute ; etiology ; genetics ; pathology ; Mutation ; genetics

Although the traditional chemotherapy has achieved a certain effect for patients with acute myeloid leukemia (AML), but there are still limitations in terms of improving the rate of complete remission and overcome relapse after remission. The further study found that many cytogenetic molecular and epigenetic abnormalities occurred during the progression of AML, such as abnormal expression of cell surface molecules, mutation, gene aberrant methylation and so on. The drugs targeted at these changes can improve the prognosis for patients, and provide a new way for treating patients with AML. At present, the mostly targeted drugs include monoclonal antibodies CD33-Ab, tyrosine kinase inhibitor, inhibitors of DNA methyltransferases inhibitors and so on. In this review, the progress of targeted therapy in AML treatment is summarized.
Antibodies, Monoclonal ; therapeutic use ; DNA Modification Methylases ; antagonists & inhibitors ; Humans ; Leukemia, Myeloid, Acute ; drug therapy ; Mutation ; Prognosis ; Protein Kinase Inhibitors ; therapeutic use ; Remission Induction

Animals ; DNA Methylation ; DNA-Cytosine Methylases ; chemistry ; metabolism ; physiology ; Embryonic Development ; physiology ; Humans ; Mice ; Site-Specific DNA-Methyltransferase (Adenine-Specific) ; chemistry ; metabolism ; physiology